|Day Low/High||38.27 / 40.13|
|52 Wk Low/High||27.77 / 56.74|
Let's see if this new name is worth buying.
Data and industry conferences will likely be catalysts for shares in the space.
Here's a rundown of four technical setups that are showing solid trading potential.
Celgene's days of stellar growth will continue to stretch far into the future.
The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.
Risks far outweigh the possible rewards of buying into late bullishness.
At the very least, move those stop loss levels in very close on long positions.
Follow these maxims and you should do well in this volatile sector.
TheStreet's Jim Cramer answers viewers' questions on Allergan, Pfizer, Disney, MasterCard, Chipotle, Under Armour and more.
Throughout this historic run, four groups have consistently led the market.
As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.